Androgen Deprivation Therapy Muscle Protein Metabolism and Blood Glucose
Status:
Recruiting
Trial end date:
2022-08-01
Target enrollment:
Participant gender:
Summary
Prostate cancer (PCa) patients receiving androgen deprivation therapy (ADT) (e.g., Zoladex),
experience troublesome side effects during and after treatment (e.g., loss of lean body mass
(LBM) and increased fat mass). Although the negative effects of ADT on muscle mass are well
documented, the cellular effects of ADT on muscle tissue are still largely unknown, and
studies investigating the mechanisms are highly warranted. Furthermore, understanding the
cellular mechanisms through which ADT negatively influences muscle mass and glucose
metabolism is important so that appropriate measures can be taken to counteract muscle
wasting and comorbidities during ADT. Thus, PCa patients on ADT (Zoladex), along with non-ADT
treated PCa patients serving as controls, will be invited to participate in this study, that
aims to investigate the influence of ADT on the basal muscle protein turnover, as well as the
responses to strength training. Secondary aims are to investigate between-group differences
in blood glucose and insulin responses following a meal).
Phase:
N/A
Details
Lead Sponsor:
Norwegian School of Sport Sciences
Collaborators:
King's College London Oslo University Hospital Rigshospitalet, Denmark University Hospital, Akershus University of Copenhagen